Energenesis Biomedical Co Ltd
TWSE:6657
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Energenesis Biomedical Co Ltd
TWSE:6657
|
TW |
|
Yonyou Network Technology Co Ltd
SSE:600588
|
CN |
|
G
|
Grupo Rotoplas SAB de CV
BMV:AGUA
|
MX |
|
Lotes Co Ltd
TWSE:3533
|
TW |
Energenesis Biomedical Co Ltd
Energenesis Biomedical Co., Ltd. engages in the development of new drugs. The company is headquartered in Taipei City, Taipei. The company went IPO on 2018-08-08. The firm's main product projects include experimental service analysis and reagent sales. The firm's main new drugs include ENERGI-F703, ENERGI-F701, ENERGI-F711, and ENERGI-F706. The ENERGI-F703 indications are diabetic foot ulcers. The ENERGI-F701 indications are abnormal alopecia. The ENERGI-F711 indications are burns. The ENERGI-F706 indications are cachexia.
Energenesis Biomedical Co., Ltd. engages in the development of new drugs. The company is headquartered in Taipei City, Taipei. The company went IPO on 2018-08-08. The firm's main product projects include experimental service analysis and reagent sales. The firm's main new drugs include ENERGI-F703, ENERGI-F701, ENERGI-F711, and ENERGI-F706. The ENERGI-F703 indications are diabetic foot ulcers. The ENERGI-F701 indications are abnormal alopecia. The ENERGI-F711 indications are burns. The ENERGI-F706 indications are cachexia.